NOVA continues to expand across therapeutic modalities and targets, demonstrating the flexibility of incentive-driven discovery and its potential for scalable drug r&d and partnerships. after receiving 8,446 unique nanobody submissions for PD-L1 (and seeing rapid improvement across confidence and physical interaction metrics) we are now moving the NOVA nanobody competition to IL-6 in partnership w/ @Yalotein IL-6 is one of the central cytokines behind inflammation and immune regulation and a clinically validated pathway behind multi-billion dollar autoimmune drugs. seeing measurable improvement emerge from open competition this quickly is really exciting. we are now applying the same decentralized discovery framework to a very different therapeutic area with implications across inflammation and immune modulation. these are core biological processes underlying aging and many of the most common chronic diseases affecting humanity. the ability to precisely modulate immune signaling could become one of the defining therapeutic frontiers of this century. interested in scaling discovery? contact us.